Maria Giovanna Dal Bello

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Biagio Ricciuti, Carlo Genova, Andrea De Giglio et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 362 citations · Full text

Medicine, Immunology, Oncology +16

The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

Maria Giovanna Dal Bello, Rosangela Filiberti, Angela Alama et al. · Journal of Translational Medicine · 2019 · 203 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer

Caroline A. Nebhan, Alessio Cortellini, Weijie Ma et al. · JAMA Oncology · 2021 · 152 citations · Full text

Medicine, Immunology, Oncology +17

Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

Sandra Salvi, Vincenzo Fontana, Simona Boccardo et al. · Cancer Immunology Immunotherapy · 2012 · 134 citations · Full text

Medicine, Immunology, Oncology +15

Radiomic Detection of EGFR Mutations in NSCLC

Giovanni Rossi, Emanuele Barabino, Alessandro Fedeli et al. · Cancer Research · 2020 · 111 citations · Full text

Medicine, Oncology, Radiology +17